Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIRI vs Regorafenib in mCRC with CCND1 A/A Genotype
NCT03829462Phase 3Active, not recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Mar 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan in metastatic colorectal cancer (mCRC), sponsored by Institut du Cancer de Montpellier. Started Mar 2019; status: active, not recruiting.
02
Drugs
irinotecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03829462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829462.